Filing Analysis
BriaCell Therapeutics Corp. filed an 8-K to disclose unaudited condensed interim consolidated financial statements and management's discussion and analysis for its subsidiary, BriaPro Therapeutics Corp., for the periods ended April 30, 2026.
📋 Key Facts
- Filing date: June 26, 2026
- Subsidiary involved: BriaPro Therapeutics Corp.
- Reporting period: Three and nine months ended April 30, 2026
- Content includes unaudited condensed interim consolidated financial statements (Exhibit 99.1) and MD&A (Exhibit 99.2).
BriaCell Therapeutics Corp. completed a best-efforts offering of 1,449,300 common shares at $3.25 per share, raising gross proceeds of $4.71 million. The funds are earmarked for working capital and general corporate purposes.
🚩 Red Flags
- The offering was conducted on a 'best efforts' basis, which is generally less certain than firmly underwritten offerings.
- Dilution: The issuance of nearly 1.45 million shares increases the total share count.
📋 Key Facts
- Offering closed on June 2, 2026 (though text contains a likely typo mentioning 2025).
- Gross proceeds totaled $4.71 million from the sale of 1,449,300 common shares.
- Offering price was $3.25 per common share.
- Placement Agent (ThinkEquity LLC) received a 7.5% cash fee and warrants to purchase 72,465 common shares at $4.0625 per share.
- Shares were sold under an existing S-3 registration statement (File No. 333-276650).
BriaCell Therapeutics Corp. announced that its subsidiary, BriaPro Therapeutics Corp., has filed its unaudited condensed interim consolidated financial statements and MD&A for the period ended January 31, 2026, with Canadian securities regulators.
📋 Key Facts
- The filing pertains to subsidiary BriaPro Therapeutics Corp.
- Financials cover the three and six-month periods ended January 31, 2026.
- Filings were made with the British Columbia Securities Commission and Alberta Securities Commission.
- The information is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
BriaCell Therapeutics Corp. reported the results of its Annual General and Special Meeting held on March 5, 2026. Shareholders ratified the appointment of the company's auditors, elected six directors, and re-approved the omnibus equity incentive plan.
📋 Key Facts
- The meeting was held on March 5, 2026, with 3,502,695 shares represented out of 7,250,487 outstanding (approx. 48.3% quorum).
- MNP LLP was ratified as the independent auditor with 3,431,761 votes in favor.
- Six directors were elected: Dr. Jane Gross, Mr. Jamieson Bondarenko, Dr. William V. Williams, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg.
- The Omnibus Equity Incentive Plan was re-approved with 1,524,081 votes for, 362,949 against, and 1,615,665 broker non-votes.
BriaCell Therapeutics (BCTX) is transferring its exclusive license to develop and commercialize Soluble CD80 (a cancer therapeutic) to its majority-owned subsidiary BriaPro Therapeutics via an asset purchase agreement dated February 18, 2026. In exchange, BriaPro will issue 23,972,589 common shares to BriaCell, increasing BriaCell's ownership to ~78%, and BriaCell will provide up to $3.0 million in credit facility funding for R&D.
🚩 Red Flags
- Related-party transaction: asset transfer between parent (BriaCell) and majority-owned subsidiary (BriaPro) — potential for value extraction or unfair pricing
- Key IP asset (Soluble CD80 exclusive license) being moved to a subsidiary structure, which could complicate future valuation and investor transparency
- BriaCell committing up to $3.0M in additional funding to subsidiary on top of the asset transfer
- Multiple warrant classes (BCTXW, BCTXZ, BCTXL) indicate history of dilutive financings
- Subsidiary structure may create additional layers between investors and the core therapeutic asset
📋 Key Facts
- BriaCell entered an asset purchase agreement with majority-owned subsidiary BriaPro Therapeutics on February 18, 2026
- BriaPro will acquire BriaCell's exclusive license to develop and commercialize Soluble CD80 as a cancer therapeutic
- Consideration: BriaPro will issue 23,972,589 common shares to BriaCell, increasing BriaCell's ownership to approximately 78%
- BriaCell will provide up to $3.0 million credit facility to BriaPro for R&D, subject to per-drawdown approval
- Expected closing date: on or about March 12, 2026
- Closing conditions include disinterested shareholder approval of BriaPro and an independent third-party valuation
- Company is incorporated in British Columbia, Canada; listed on Nasdaq (BCTX)
- BriaCell is an emerging growth company
- Multiple warrant classes trade on Nasdaq (BCTXW, BCTXZ, BCTXL)
BriaCell Therapeutics Corp. completed a public offering of Common Units and Pre-funded Units on January 15, 2026, raising approximately $30 million in gross proceeds. The offering includes various warrant types to purchase common shares at different exercise prices.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 4 million units and various warrant classes (Common, Pre-funded, and Placement Agent Warrants).
- Pre-funded warrants with a near-zero exercise price ($0.001) represent highly dilutive equity for existing shareholders.
📋 Key Facts
- Total aggregate gross proceeds: approximately $30 million (before fees).
- Sold 4,327,530 Common Units at $5.59 per unit.
- Sold 1,039,196 Pre-funded Units at $5.589 per unit.
- Common Warrants have an exercise price of $6.93 and are exercisable for five years.
- Pre-funded Warrants have a nominal exercise price of $0.001 per share.
- Placement Agent (ThinkEquity LLC) received a 6.25% cash fee on aggregate gross proceeds.
- Issued Placement Agent Warrants to purchase up to 161,001 common shares at an exercise price of $8.385.
BriaCell Therapeutics Corp. filed an 8-K to provide unaudited condensed interim consolidated financial statements and management's discussion and analysis (MD&A) for its two-third owned subsidiary, BriaPro Therapeutics Corp., for the period ended October 31, 2025.
📋 Key Facts
- The filing pertains to a subsidiary, BriaPro Therapeutics Corp., which is 66.7% (two-thirds) owned by BriaCell.
- Financial statements and MD&A cover the three-month period ended October 31, 2025.
- Information was filed with the British Columbia Securities Commission and Alberta Securities Commission.
- The disclosure is provided under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
BriaCell Therapeutics Corp. has filed consolidated financial statements and management's discussion and analysis (MD&A) for its two-thirds owned subsidiary, BriaPro Therapeutics Corp., for the period ended July 31, 2025.
📋 Key Facts
- The filing pertains to a subsidiary, BriaPro Therapeutics Corp., which is 66.7% (two-thirds) owned by BriaCell.
- Financial statements and MD&A cover the period ending July 31, 2025.
- Documents were filed with the British Columbia Securities Commission and Alberta Securities Commission.
- The information was provided under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
BriaCell Therapeutics Corp. completed a 1-for-10 reverse stock split effective August 25, 2025. The consolidation of common shares resulted in one post-consolidation share for every ten pre-consolidation shares.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing compliance).
📋 Key Facts
- Consolidation ratio: 1 post-Consolidation Common Share for every 10 pre-Consolidation Common Shares.
- Effective date of consolidation: August 25, 2025.
- New CUSIP number: 107930307.
- Trading resumed on Nasdaq and TSX at market open on August 25, 2025.
BriaCell Therapeutics Corp. completed a public offering of Common Units and Pre-funded Units, raising approximately $15 million in gross proceeds. The offering includes warrants with an exercise price of $1.50 per share.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 10 million new units and accompanying warrants.
- Warrants with a $1.50 exercise price may be out-of-the-money depending on current market price, but the pre-funded warrants at $0.001 represent significant immediate dilution upon exercise.
📋 Key Facts
- Offered 10,775,000 Common Units at $1.25 per unit and 1,225,000 Pre-funded Units at $1.249 per unit.
- Aggregate gross proceeds are approximately $15 million before fees.
- Common Units include one common share and one warrant to purchase one common share at $1.50.
- Pre-funded Warrants are immediately exercisable at $0.001 per share.
- Placement Agent (ThinkEquity LLC) received a 7.5% cash fee on aggregate gross proceeds.
- The offering was conducted under an S-1 Registration Statement declared effective July 15, 2025.
BriaCell Therapeutics Corp. is disclosing the filing of unaudited condensed interim consolidated financial statements for its two-third owned subsidiary, BriaPro Therapeutics Corp., covering the periods ended April 30, 2025.
📋 Key Facts
- Subsidiary involved: BriaPro Therapeutics Corp. (2/3 owned by BriaCell).
- Reporting period: Three and nine months ended April 30, 2025.
- Nature of disclosure: Unaudited condensed interim consolidated financial statements and MD&A.
- Filing date of report: June 16, 2025.
BriaCell Therapeutics Corp. completed a public offering of units and pre-funded units, raising approximately $12.0 million in gross proceeds to fund working capital and business objectives. The offering included the issuance of warrants and triggered an over-allotment option by the Representative.
🚩 Red Flags
- Dilutive nature of the offering: Issuance of over 2.6 million units containing warrants will lead to significant future dilution upon exercise.
- Pre-funded Units: The use of pre-funded units often indicates a desire to avoid immediate large-scale ownership thresholds or specific regulatory/voting constraints, but results in similar long-term dilution.
📋 Key Facts
- Completed public offering of 2,005,967 Units at $4.50 per Unit and 660,700 Pre-funded Units at $4.499 per Pre-funded Unit.
- Aggregate gross proceeds of approximately $12.0 million from the primary offering.
- Representative exercised an over-allotment option for 399,999 common shares and 399,999 Warrants, adding ~$1.8 million in gross proceeds.
- Warrants (BCTXZ) commenced trading on Nasdaq Capital Market on April 25, 2025.
- The offering was conducted via a firm commitment underwriting agreement with ThinkEquity LLC.
- Proceeds are earmarked for working capital, general corporate purposes, and advancement of business objectives.
BriaCell Therapeutics Corp. filed an 8-K to disclose unaudited condensed interim consolidated financial statements and management's discussion and analysis for its two-third owned subsidiary, BriaPro Therapeutics Corp., for the periods ended January 31, 2025.
📋 Key Facts
- Disclosure pertains to a two-third (2/3) owned subsidiary: BriaPro Therapeutics Corp.
- Reporting period covers the three and six month periods ended January 31, 2025.
- Financial statements were filed with the British Columbia Securities Commission and Alberta Securities Commission.
- The information is provided under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
BriaCell Therapeutics Corp. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving the deficiency notice issued in August 2024.
🚩 Red Flags
- Historical delisting risk (the company was under threat of delisting since August 22, 2024).
📋 Key Facts
- Received written notice from Nasdaq Staff on February 12, 2025, confirming compliance with the Minimum Bid Price Requirement.
- The previous non-compliance was based on a failure to maintain a $1.00 minimum bid price over 30 consecutive business days.
- The matter regarding the deficiency notice is now officially closed.
BriaCell Therapeutics Corp. held its Annual General Meeting of Shareholders on February 5, 2025. The meeting resulted in the ratification of MNP LLP as auditors and the election of six directors.
🚩 Red Flags
- Recent 1-for-15 reverse stock split (effective Jan 24, 2025) is a significant red flag often used to maintain Nasdaq compliance or address low share prices.
📋 Key Facts
- Annual General Meeting (AGM) held on February 5, 2025.
- Shareholders ratified the appointment of MNP LLP as company auditors.
- Six nominees were elected to serve on the Board of Directors until the next annual meeting or successors are elected.
- The filing notes a 1-for-15 reverse stock split that became effective on January 24, 2025.
BriaCell Therapeutics Corp. completed a best-efforts equity offering of 762,500 common shares at $4.00 per share, raising gross proceeds of $3.05 million. The funds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Dilutive offering: Issuance of new common shares at $4.00 per share
- Warrant issuance to placement agent: 38,125 warrants issued as compensation, which may lead to further dilution upon exercise
📋 Key Facts
- Offering size: 762,500 common shares
- Offering price: $4.00 per common share
- Gross proceeds: $3.05 million (before fees)
- Placement Agent: ThinkEquity LLC
- Agent compensation: 7.5% cash fee plus 38,125 warrants with a $5.00 exercise price
- Offering closed on February 5, 2025
- Shares issued under an existing S-3 registration statement (File No. 333-276650)
BriaCell Therapeutics Corp. has completed a 1-for-15 reverse stock split effective January 24, 2025. The consolidated shares are scheduled to begin trading on the Nasdaq and TSX under a new CUSIP on January 29, 2025.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing compliance).
📋 Key Facts
- Consolidation ratio: 1 post-Consolidation Common Share for every 15 pre-Consolidation Common Shares.
- Effective date of consolidation: January 24, 2025.
- New trading commencement date: January 29, 2025.
- Exchanges: The Nasdaq Capital Market and the Toronto Stock Exchange (TSX).
- New CUSIP number: 107930208.
BriaCell Therapeutics Corp. has announced a 1-for-15 reverse stock split to maintain compliance with Nasdaq listing requirements. The consolidation is expected to take effect on January 24, 2025, with new shares trading on January 29, 2025.
🚩 Red Flags
- Reverse stock split (1-for-15) typically indicates a low share price and potential delisting risk.
- Explicit mention of needing the split to 'ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market'.
📋 Key Facts
- Consolidation ratio: 1 post-Consolidation Common Share for every 15 pre-Consolidation Common Shares.
- Purpose: To ensure continued compliance with Nasdaq listing requirements.
- Expected effective date: January 24, 2025.
- Trading commencement of new shares: January 29, 2025 (subject to exchange confirmation).
- The consolidation is subject to approval by the Toronto Stock Exchange (TSX).
BriaCell Therapeutics Corp. announced the rescheduling of its 2025 Annual General Meeting of Shareholders from January 23, 2025, to February 5, 2025.
📋 Key Facts
- The 2025 Annual General Meeting (AGM) has been moved from Jan 23, 2025, to Feb 5, 2025.
- New meeting time is 9:00 a.m. Eastern Time.
- Meeting location remains/is set for Suite 3400, One First Canadian Place, Toronto, ON.
- The record date of December 9, 2024, remains unchanged.
BriaCell Therapeutics Corp. filed an 8-K to provide unaudited condensed interim consolidated financial statements and management's discussion and analysis for its two-third owned subsidiary, BriaPro Therapeutics Corp., for the period ended October 31, 2024.
📋 Key Facts
- The filing pertains to a subsidiary, BriaPro Therapeutics Corp., which is 66.7% (two-thirds) owned by BriaCell.
- Financial statements and MD&A cover the three-month period ended October 31, 2024.
- The information was filed with the British Columbia Securities Commission and Alberta Securities Commission.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
BriaCell Therapeutics Corp. completed a public offering of 7,400,000 units consisting of one common share and one warrant per unit at $0.75 per unit. The offering raised approximately $5.55 million in gross proceeds to fund working capital and business objectives.
🚩 Red Flags
- Significant dilution: Issuance of 7.4 million new shares and warrants at a price ($0.75) below the warrant exercise price ($0.9375).
- Capital raise necessity: Use of proceeds for 'working capital requirements' often indicates a need to extend cash runway in pre-revenue biotech firms.
📋 Key Facts
- Offered 7,400,000 Units at a combined price of $0.75 per Unit.
- Each Unit includes one common share and one warrant to purchase up to one common share.
- Warrant exercise price is $0.9375 per share; warrants expire in five years.
- Gross proceeds from the offering totaled approximately $5.55 million.
- The offering closed on December 13, 2024.
- Company issued 370,000 Representative's Warrants to the Underwriter (ThinkEquity LLC).
BriaCell Therapeutics Corp. announced the resignation of Marc Lustig from its Board of Directors, effective November 23, 2024.
📋 Key Facts
- Marc Lustig resigned from the Board of Directors on November 23, 2024.
- The company expressed gratitude for his contributions during his tenure.
BriaCell Therapeutics Corp. filed an 8-K to provide consolidated financial statements and management's discussion and analysis (MD&A) for its two-thirds owned subsidiary, BriaPro Therapeutics Corp., for the period ended July 31, 2024.
📋 Key Facts
- The filing relates to a subsidiary, BriaPro Therapeutics Corp., which is 66.7% (two-thirds) owned by BriaCell.
- Financial statements and MD&A cover the period ending July 31, 2024.
- Information was filed under Item 7.01 (Regulation FD Disclosure).
- The disclosure is provided to satisfy filing requirements with the British Columbia Securities Commission and Alberta Securities Commission.
BriaCell Therapeutics Corp. entered into a placement agency agreement to conduct a best-efforts offering of common shares and warrants, raising approximately $5.0 million in gross proceeds.
🚩 Red Flags
- Dilutive offering: Issuance of over 5 million new shares and warrants at a combined price of $0.975.
- Warrant overhang: The issuance of warrants with an exercise price ($0.85) below the current unit price ($0.975) creates immediate dilution potential.
📋 Key Facts
- Offering size: 5,128,500 common shares and 5,128,500 Common Warrants.
- Combined offering price per share/warrant unit: $0.975.
- Common Warrant exercise price: $0.85 per share (immediately exercisable).
- Gross proceeds from the offering: approximately $5.0 million.
- Placement Agent (ThinkEquity LLC) received a 7.5% cash fee and 256,425 warrants with an exercise price of $1.21875.
- Use of proceeds: working capital, general corporate purposes, and advancement of business objectives.
BriaCell Therapeutics Corp. issued an 8-K to announce positive clinical data from its Phase 2 study, reporting a dramatic anti-tumor response and complete resolution of metastasis in a patient treated with Bria-IMT™ plus an immune checkpoint inhibitor.
📋 Key Facts
- Reported 'dramatic anti-tumor response' in a Phase 2 study.
- Observed complete resolution of temporal lobe breast cancer metastasis in a specific patient.
- Regimen used: Bria-IMT™ plus an immune checkpoint inhibitor.
- Filing date: October 1, 2024.
BriaCell Therapeutics Corp. completed a best-efforts offering of 12,325,000 common shares at $0.69 per share to raise approximately $8.5 million in gross proceeds. The capital is intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: Issuance of over 12 million shares at a low price point ($0.69)
- Warrant overhang: Placement agent received warrants that will cause further dilution upon exercise
- Capital raise necessity: Use of proceeds for 'working capital' often indicates a need to extend cash runway in biotech firms.
📋 Key Facts
- Offering size: 12,325,000 common shares
- Offering price: $0.69 per share
- Gross proceeds: $8,504,250 (before fees)
- Placement Agent: ThinkEquity LLC
- Agent compensation: 7.5% cash fee plus 616,250 warrants
- Warrant terms: 5-year term, exercisable starting March 11, 2025, at $0.8625 per share
- Closing date: September 12, 2024
BriaCell Therapeutics Corp. issued an 8-K reporting multiple positive clinical and regulatory developments, including a successful pre-IND meeting with the FDA and positive survival data from its Phase 2 Bria-IMT™ study in metastatic breast cancer.
📋 Key Facts
- Announced a poster presentation for the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Nov 6-10, 2024).
- Reported positive outcomes from a pre-investigational new drug (pre-IND) meeting with the U.S. FDA.
- Released positive six-month overall survival data from its Phase 2 clinical study of Bria-IMT™ combined with an immune checkpoint inhibitor for late-stage metastatic breast cancer.
BriaCell Therapeutics Corp. received a deficiency letter from Nasdaq because its common shares have closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until February 18, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq minimum bid price requirement).
- Potential for a mandatory reverse stock split to regain compliance.
- Risk of delisting from Nasdaq if compliance is not achieved by February 18, 2025.
📋 Key Facts
- Received a deficiency letter from Nasdaq on August 22, 2024.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- The company has a 180-day period to regain compliance (deadline: February 18, 2025).
- Compliance can be achieved if the stock closes at or above $1.00 for 10 consecutive business days.
- A second 180-day grace period may be available if other listing standards are met and a reverse split is utilized to cure the deficiency.
BriaCell Therapeutics Corp. issued a press release regarding positive clinical data from its Phase 2 study of the Bria-IMT™ regimen in combination with an immune checkpoint inhibitor for metastatic breast cancer.
📋 Key Facts
- The company reported significantly higher progression-free survival (PFS) for its top responder patient.
- The study involves the Bria-IMT™ regimen used in combination with an immune checkpoint inhibitor.
- The clinical context is a Phase 2 study targeting metastatic breast cancer.
- Data was released via press release on July 18, 2024.
BriaCell Therapeutics Corp. received a notice from Nasdaq stating it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement for 33 consecutive business days. The company has been granted a 180-day compliance period ending December 30, 2024.
🚩 Red Flags
- Delisting notice due to failure to meet minimum market value requirements.
- Potential for delisting if compliance is not met by December 30, 2024.
- Market capitalization/MVLS has fallen below the $35M threshold required for Nasdaq Capital Market listing.
📋 Key Facts
- Nasdaq notified the company on July 3, 2024, regarding non-compliance with Nasdaq Listing Rule 5550(b)(2).
- The failure is based on Market Value of Listed Securities (MVLS) falling below $35,000,000 for the period from May 15, 2024, to July 2, 2024.
- A compliance period has been granted until December 30, 2024.
- To regain compliance, MVLS must be $35,000,000 or more for at least ten consecutive business days during the compliance period.
BriaCell Therapeutics Corp. filed this 8-K to provide unaudited condensed interim financial statements and management's discussion and analysis (MD&A) for its two-thirds owned subsidiary, BriaPro Therapeutics Corp., for the periods ended April 30, 2024.
📋 Key Facts
- The filing pertains to a subsidiary, BriaPro Therapeutics Corp., which is 2/3 owned by BriaCell Therapeutics Corp.
- Financial statements and MD&A cover the three and nine months ended April 30, 2024.
- The information was filed with the British Columbia Securities Commission and Alberta Securities Commission.
BriaCell Therapeutics Corp. completed a $5 million securities offering involving the issuance of common shares and warrants to various investors. The proceeds are intended for working capital and funding Phase 3 clinical studies in advanced breast cancer.
🚩 Red Flags
- Dilutive offering: Issuance of significant number of shares and warrants will dilute existing shareholders.
- Related party transaction: A director participated in the offering, purchasing 902,935 shares at a premium ($2.215) compared to other investors ($2.00).
- High placement agent fees: The company is paying a 7.0% cash fee plus expense reimbursements.
📋 Key Facts
- Gross proceeds from the offering totaled $5,000,000 before fees.
- The offering included 2,302,935 common shares, 100,000 pre-funded warrants, and up to 2,402,935 common warrants.
- A director of the Company purchased 902,935 shares at a combined price of $2.215 per share (including warrants).
- Pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share.
- Common Warrants are exercisable six months from issuance at $2.11 per share.
- The company entered into a 90-day standstill agreement regarding the issuance of new equity or convertible securities.
BriaCell Therapeutics Corp. announced the filing of unaudited condensed interim financial statements and management's discussion and analysis for its two-thirds owned subsidiary, BriaPro Therapeutics Corp., for the periods ended January 31, 2024.
📋 Key Facts
- The filing pertains to a subsidiary, BriaPro Therapeutics Corp., which is 2/3 owned by BriaCell Therapeutics Corp.
- Financial statements and MD&A cover the three and six months ended January 31, 2024.
- Documents were filed with the British Columbia Securities Commission and Alberta Securities Commission.
BriaCell Therapeutics Corp. held its Annual General Meeting of Shareholders on January 30, 2024. The meeting resulted in the ratification of MNP LLP as auditors and the election of seven directors.
📋 Key Facts
- Annual General Meeting (AGM) held on January 30, 2024.
- Shareholders ratified the appointment of MNP LLP as company auditors.
- Seven nominees for the Board of Directors were elected to serve until the next annual meeting or until successors are appointed.
- Quorum was established with 5,375,071 common shares represented (approx. 33.6% of outstanding shares).
- Total common shares entitled to vote as of Dec 20, 2023: 15,981,726.